Literature DB >> 33591379

Natural history of untreated kidney cancer.

Kristen McAlpine1, Antonio Finelli2.   

Abstract

Entities:  

Keywords:  Active surveillance; Kidney cancer; Watchful waiting

Mesh：

Year:  2021        PMID： 33591379     DOI： 10.1007/s00345-020-03578-1

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


× No keyword cloud information.
  30 in total

1.  Challenges Interpreting Chemoprevention Studies Using Observational Data.

Authors:  Madhur Nayan; David N Juurlink; Antonio Finelli; Girish Kulkarni; Robert J Hamilton
Journal:  J Clin Oncol       Date:  2017-12-20       Impact factor: 44.544

Review 2.  Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis.

Authors:  Marc C Smaldone; Alexander Kutikov; Brian L Egleston; Daniel J Canter; Rosalia Viterbo; David Y T Chen; Michael A Jewett; Richard E Greenberg; Robert G Uzzo
Journal:  Cancer       Date:  2011-07-15       Impact factor: 6.860

3.  Small Renal Mass Surveillance: Histology-specific Growth Rates in a Biopsy-characterized Cohort.

Authors:  Antonio Finelli; Douglas C Cheung; Ashraf Al-Matar; Andrew J Evans; Christopher G Morash; Stephen E Pautler; D Robert Siemens; Simon Tanguay; Ricardo A Rendon; Martin E Gleave; Darrel E Drachenberg; Joseph L Chin; Neil E Fleshner; Masoom A Haider; John R Kachura; Jenna Sykes; Michael A S Jewett
Journal:  Eur Urol       Date:  2020-07-14       Impact factor: 20.096

4.  Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.

Authors:  Rajiv Puri; Victor Palit; Paul M Loadman; Michael Flannigan; Tariq Shah; Guzanfar A Choudry; Saurajyoti Basu; John A Double; Gino Lenaz; Shanta Chawla; Mario Beer; Coen Van Kalken; Richard de Boer; Jos H Beijnen; Christopher J Twelves; Roger M Phillips
Journal:  J Urol       Date:  2006-10       Impact factor: 7.450

5.  Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.

Authors:  Phillip M Pierorazio; Michael H Johnson; Mark W Ball; Michael A Gorin; Bruce J Trock; Peter Chang; Andrew A Wagner; James M McKiernan; Mohamad E Allaf
Journal:  Eur Urol       Date:  2015-02-16       Impact factor: 20.096

6.  Clinical Stage Migration and Survival for Renal Cell Carcinoma in the United States.

Authors:  Hiten D Patel; Mohit Gupta; Gregory A Joice; Arnav Srivastava; Ridwan Alam; Mohamad E Allaf; Phillip M Pierorazio
Journal:  Eur Urol Oncol       Date:  2018-09-25

7.  The natural history of incidentally detected small renal masses.

Authors:  Alessandro Volpe; Tony Panzarella; Ricardo A Rendon; Masoom A Haider; Filippos I Kondylis; Michael A S Jewett
Journal:  Cancer       Date:  2004-02-15       Impact factor: 6.860

8.  The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment.

Authors:  Bimal Bhindi; R Houston Thompson; Christine M Lohse; Ross J Mason; Igor Frank; Brian A Costello; Aaron M Potretzke; Robert P Hartman; Theodora A Potretzke; Stephen A Boorjian; John C Cheville; Bradley C Leibovich
Journal:  Eur Urol       Date:  2018-07-13       Impact factor: 20.096

9.  Growth Rates of Genetically Defined Renal Tumors: Implications for Active Surveillance and Intervention.

Authors:  Mark W Ball; Julie Y An; Patrick T Gomella; Rabindra Gautam; Christopher J Ricketts; Cathy D Vocke; Laura S Schmidt; Maria J Merino; Ramaprasad Srinivasan; Ashkan A Malayeri; Adam R Metwalli; W Marston Linehan
Journal:  J Clin Oncol       Date:  2020-02-21       Impact factor: 44.544

Review 10.  Active surveillance of small renal masses.

Authors:  Carmen Sebastià; Daniel Corominas; Mireia Musquera; Blanca Paño; Tarek Ajami; Carlos Nicolau
Journal:  Insights Imaging       Date:  2020-05-05
View more
  1 in total

1.  Renal cancer: overdiagnosis and overtreatment.

Authors:  Giuseppe Rosiello; Alessandro Larcher; Francesco Montorsi; Umberto Capitanio
Journal:  World J Urol       Date:  2021-08       Impact factor: 4.226
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.